SQZ Biotechnologies Co. (SQZ) News

SQZ Biotechnologies Co. (SQZ): $0.44

0.17 (+61.11%)

POWR Rating

Component Grades

Momentum

F

Stability

C

Sentiment

Quality

C

Add SQZ to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#97 of 387

in industry

Filter SQZ News Items

SQZ News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

SQZ News Highlights

  • For SQZ, its 30 day story count is now at 2.
  • Over the past 1 day, the trend for SQZ's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about SQZ are LI, UL and CELL.

Latest SQZ News From Around the Web

Below are the latest news stories about SQZ BIOTECHNOLOGIES CO that investors may wish to consider to help them evaluate SQZ as an investment opportunity.

SQZ Biotechnologies to effect 1-for-10 reverse stock split

  • SQZ Biotechnologies (NYSE:SQZ) has approved a 1-for-10 reverse stock split of its common stock, effective on July 6, after market close.
  • On the effective date, every 10 common shares issued and outstanding will be automatically combined into one share of common stock.
  • The company ahs received notice from NYSE over not being compliant as average global market capitalization over a consecutive 30 day trading day period was less than $50 million and, at the same time, its last reported stockholders’ equity was less than $50 million.
  • Source: Seeking Alpha | June 16, 2023

SQZ Biotechnologies to Consolidate Shares with 1-for-10 Reverse Stock Split

WATERTOWN, Mass., June 15, 2023--SQZ Biotechnologies Company (NYSE: SQZ) (the "Company" or "SQZ"), focused on unlocking the full potential of cell therapies, today announced that its Board of Directors (the "Board") has approved a 1-for-10 reverse stock split ("reverse split") of its common stock, par value $0.001 per share ("Common Stock"), that is expected to become effective on Thursday, July 6, 2023 at 5:00 p.m. Eastern Time (the "Effective Date"). The Company’s common stock is expected to b

Yahoo | June 15, 2023

SQZ Biotechnologies Company (SQZ) Reports Q1 Loss, Misses Revenue Estimates

SQZ Biotechnologies Company (SQZ) delivered earnings and revenue surprises of -11.11% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | May 10, 2023

SQZ Biotechnologies Reports First Quarter 2023 Financial Results and Recent Portfolio Updates

WATERTOWN, Mass., May 10, 2023--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies, today reported first quarter 2023 financial results and recent portfolio updates.

Yahoo | May 10, 2023

Denali Therapeutics Inc. (DNLI) Reports Q1 Loss, Tops Revenue Estimates

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -12.68% and 15.13%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | May 8, 2023

Investors Aren't Entirely Convinced By SQZ Biotechnologies Company's (NYSE:SQZ) Revenues

With a price-to-sales (or "P/S") ratio of 0.9x SQZ Biotechnologies Company ( NYSE:SQZ ) may be sending very bullish...

Yahoo | April 17, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

We're starting off the day with a look at the biggest pre-market stock movers traders need to know about on Thursday morning!

William White on InvestorPlace | March 23, 2023

SQZ Biotech's Cancer Candidate Shows Response At Low Dose In HPV16+ Solid Tumor Patient

SQZ Biotechnologies Company (NYSE: SQZ) announced that a confirmed complete response was observed in the first patient in the lowest-dose cohort of the Phase 1 SQZ-AAC-HPV-101 trial. The second and third patients have also been enrolled in the trial. The company has completed the dose-limiting toxicity period for the lowest-dose cohort. The Study Safety Committee has completed its review and recommends that the company enroll patients in the highest dose cohort. The company anticipates initial c

Yahoo | March 23, 2023

SQZ Biotechnologies Announces Confirmed Complete Response in HPV16+ Solid Tumor Patient in the Lowest-Dose Cohort of the SQZ-AAC-HPV-101 Clinical Trial

WATERTOWN, Mass., March 22, 2023--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies, today announced that, according to RECIST 1.1 criteria, a confirmed complete response was observed in the first patient in the lowest-dose cohort of the Phase 1 SQZ-AAC-HPV-101 clinical trial. The company has decided to continue to enroll patients in the SQZ-AAC-HPV-101 clinical trial. The second and third patients have also been enrolled in the trial. The company

Yahoo | March 22, 2023

SQZ Biotechnologies Reports Full Year 2022 Financial Results and Recent Portfolio Updates

WATERTOWN, Mass., March 22, 2023--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies, today reported full year 2022 financial results and recent portfolio updates.

Yahoo | March 22, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!